NCT04396964

Brief Summary

The process of surgery is a controlled trauma to the body. Trauma induces changes in metabolic function that have evolved to help the body survive injury. The normal balance among use of sugar, fat, and protein for energy production is thought to change during trauma and surgery. This altered metabolic function may contribute to adverse outcomes from surgical procedures especially in the setting of patients with obesity or Type 2 Diabetes Mellitus. However, very little is known about the specific changes in metabolism that occur during surgical procedures. The main objective of this project is to describe the metabolic changes that occur during a typical surgical procedure in detail. In order to measure the alterations in the balanced use of sugar, fat, and protein during surgery we will collect blood samples from patients before, during, and after spinal surgical procedures. Subjects will be enrolled in the pre-operative hold area, give informed consent, and have a dedicated peripheral IV catheter placed. We will recruit patients who are normal weight without diabetes, obese without diabetes, and obese with diabetes. The first specific aim is to characterize the metabolic changes in sugar, fat, and protein balance during surgery in metabolically normal subjects. The second specific aim to examine if there are differences in these changes in subjects who are obese or have diabetes. The final specific aim is to measure the changes in metabolism at high resolution using a method called metabolomics, which is analogous to genome profiling. This method measures hundreds of compounds produced in different amounts as metabolic balance changes. The major impacts that may be derived from these data range from a more thorough understanding of metabolism under trauma to identification of new markers for risk stratification and intervention to improve clinical outcomes. These data will help build the foundation for new approaches to understanding the physiological and metabolic responses to stress and trauma.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
19

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Apr 2014

Longer than P75 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 14, 2014

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 3, 2016

Completed
2.7 years until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2019

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

May 15, 2020

Completed
6 days until next milestone

First Posted

Study publicly available on registry

May 21, 2020

Completed
Last Updated

May 21, 2020

Status Verified

May 1, 2020

Enrollment Period

2.6 years

First QC Date

May 15, 2020

Last Update Submit

May 15, 2020

Conditions

Outcome Measures

Primary Outcomes (4)

  • glucose

    glucose concentrations

    perioperative

  • insulin

    insulin concentrations

    perioperative

  • c-peptide

    c-peptide concentrations

    perioperative

  • cortisol

    cortisol concentrations

    perioperative

Study Arms (1)

surgery

subjects undergoing multilevel lumbar fusion

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Subjects undergoing multilevel lumbar fusion with an inhaled anesthetic.

You may qualify if:

  • Subjects were eligible if they were \>18 years old without acute or chronic health conditions who were undergoing multilevel lumbar fusions with an inhaled anesthetic.

You may not qualify if:

  • acute or chronic health conditions including cardiac, pulmonary, hepatic, renal, auto-immune, or hematological disease. Obese subjects with body mass index \>40kg/m2 were excluded. Subjects with Type 2 diabetes were eligible if they were well-controlled (HbA1c \<7.5%) and treated with diet and exercise, metformin, or insulin. Subjects were excluded if taking a sulfonylurea, thiazolidindiones, DPP-4 inhibitor, GLP-1 analog, weight loss medication, or other medications affecting glucose homeostasis.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Insulin Resistance

Condition Hierarchy (Ancestors)

HyperinsulinismGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

May 15, 2020

First Posted

May 21, 2020

Study Start

April 14, 2014

Primary Completion

November 3, 2016

Study Completion

July 31, 2019

Last Updated

May 21, 2020

Record last verified: 2020-05

Data Sharing

IPD Sharing
Will not share